



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. : 10/524,060 Confirmation No: 4405
Applicant : Zhiming SUO, M.D., Ph.D. and Barry W. FESTOFF, M.D.
Filed : February 8, 2005
Title : METHOD OF DETECTING AND PREVENTING
ALZHEIMER'S DISEASE, PARTICULARLY AT
PRODROMAL AND EARLY STAGES
Group Art Unit : 1649
Examiner : WANG, Chang Yu
Atty. Docket No. : US 1421/05(VA)
Date : October 11, 2005

SECOND
INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56 and 1.97-1.98, Applicants note herewith various references for the Examiner's consideration. These references include those cited on pages 35-44 of the application. (It is noted herewith that a copy of Reference No. 46, COWBURN et al., Receptor-G-protein signalling in Alzheimer's disease. Biochem. Soc.

Appl. No.: 10/524,060

Second Information Disclosure Statement dated October 11, 2005

Reply to Office Action of September 2, 2005

Symp., 2001, Vol 67, pp.163-175 was already submitted with the Information Disclosure Statement filed in the PTO on February 8, 2005.) The Examiner is respectfully requested to review and officially consider and make the reference(s) of record before issuing the first Office Action in connection with this case.

A completed Form 1449B/PTO listing the references thereon is enclosed herewith. (Pursuant to the PTO's Waiver signed by Deputy Commissioner Stephen G. Kunin on July 11, 2003, only the copy(ies) of foreign patent documents and non-patent literature, if applicable, is/are enclosed.) The Examiner is respectfully requested to return an initialed copy of Form1449B/PTO along with the next communication in connection with this case.

It is believed that no fee is due for this submission. Should that determination be incorrect, however, the Commissioner is hereby authorized to charge any deficiencies, or credit any overpayment, to our Deposit Account No. 01-0433, and notify the undersigned in due course.


Appl. No.: 10/524,060

Second Information Disclosure Statement dated October 11, 2005

Reply to Office Action of September 2, 2005

Should the Examiner have any questions or wish to discuss further this matter,
please contact the undersigned at the telephone number provided below.

Respectfully submitted,

A handwritten signature in black ink, appearing to be 'DA' followed by a stylized flourish.

DINESH AGARWAL
Attorney for Applicant(s)
Reg. No. 31,809

Law Office - Dinesh Agarwal, P.C.
5350 Shawnee Road, Suite 330
Alexandria, Virginia 22312
Telephone: (703) 642-9400
Fax: (703) 642-9402

DA/va

Please type a plus sign (+) inside this box →

+

PTO/SB/08B (6-95)

Approved for use through 07/31/96, OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

1449B/PTO
Rev. 10/95U.S. Department of Commerce
Patent and Trademark Office**Complete if Known****LIST OF PRIOR ART CITED BY
APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

6

Application Number

10/524,060

Filing Date

February 8, 2005

First Named Inventor

Zhiming SUO, M.D., Ph.D.

Group Art Unit

1649

Examiner Name

WANG, Chang Yu

Attorney Docket Number

US 1421/05 (VA)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Item (book), magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), Publisher, country, where published, source.	T ²
		Braak, H. & Braak, E. Neuropathological staging of Alzheimer-related changes. <i>Acta Neuropathol (Berl)</i> 82, 239-59 (1991).	
		Saitoh, T., Horsburgh, K. & Masliah, E. Hyperactivation of signal transduction systems in Alzheimer's disease. <i>Ann N Y Acad Sci</i> 695, 34-41 (1993).	
		Fowler, C.J., Cowburn, R.F., Garlind, A., Winblad, B. & O'Neill, C. Disturbances in signal transduction mechanisms in Alzheimer's disease. <i>Mol Cell Biochem</i> 149-150, 287-92 (1995).	
		Joseph, J.A., Cutler, R. & Roth, G.S. Changes in G protein-mediated signal transduction in aging and Alzheimer's disease. <i>Ann N Y Acad Sci</i> 695, 42-5 (1993).	
		Shimohama, S. et al. Aberrant phosphoinositide metabolism in Alzheimer's disease. <i>Ann N Y Acad Sci</i> 695, 46-9 (1993).	
		Matsushima, H., Shimohama, S., Chachin, M., Taniguchi, T. & Kimura, J. Ca ²⁺ -dependent and Ca ²⁺ -independent protein kinase C changes in the brain of patients with Alzheimer's disease. <i>J Neurochem</i> 67, 317-23 (1996).	
		Mattson, M.P. & Chan, S.L. Dysregulation of cellular calcium homeostasis in Alzheimer's disease: bad genes and bad habits. <i>J Mol Neurosci</i> 17, 205-24 (2001).	
		Fowler, C.J., Garlind, A., O'Neill, C. & Cowburn, R.F. Receptor-effector coupling dysfunctions in Alzheimer's disease. <i>Ann N Y Acad Sci</i> 786, 294-304 (1996).	
		Hisatomi, O. et al. A novel subtype of G-protein-coupled receptor kinase, GRK7, in teleost cone photoreceptors. <i>FEBS Lett</i> 424, 159-64. (1998).	
		Pitcher, J.A., Freedman, N.J. & Lefkowitz, R.J. G protein-coupled receptor kinases. <i>Annu Rev Biochem</i> 67, 653-92 (1998).	

Examiner
SignatureDate
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take .2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

+

PTO/SB/08B (6-95)
Approved for use through 07/31/96, OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

1449B/PTO
Rev. 10/95

U.S. Department of Commerce
Patent and Trademark Office

LIST OF PRIOR ART CITED BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/524,060
Filing Date	February 8, 2005
First Named Inventor	Zhiming SUO, M.D., Ph.D.
Group Art Unit	1649
Examiner Name	WANG, Chang Yu
Attorney Docket Number	US 1421/05 (VA)

Sheet

2

of

6

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book), magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), Publisher, country, where published, source.	T ²
		Sallese, M. et al. Regulation of G protein-coupled receptor kinase subtypes by calcium sensor proteins. <i>Biochim Biophys Acta</i> 1498, 112-21. (2000).	
		Bristow, M.R. et al. Beta-adrenergic pathways in nonfailing and failing human ventricular myocardium. <i>Circulation</i> 82, 112-25 (1990).	
		Ungerer, M., Kessebohm, K., Kronsbein, K., Lohse, M.J. & Richardt, G. Activation of beta-adrenergic receptor kinase during myocardial ischemia. <i>Circ Res</i> 79, 455-60 (1996).	
		Gros, R., Benovic, J.L., Tan, C.M. & Feldman, R.D. G-protein-coupled receptor kinase activity is increased in hypertension. <i>J Clin Invest</i> 99, 2087-93 (1997).	
		Premont, R.T., Inglese, J. & Lefkowitz, R.J. Protein kinases that phosphorylate activated G protein-coupled receptors. <i>Faseb J</i> 9, 175-82 (1995).	
		Chen, J., Makino, C.L., Peachey, N.S., Baylor, D.A. & Simon, M.I. Mechanisms of rhodopsin inactivation in vivo as revealed by a COOH-terminal truncation mutant. <i>Science</i> 267, 374-7 (1995).	
		Terwilliger, R.Z., Ortiz, J., Guitart, X. & Nestler, E.J. Chronic morphine administration increases beta-adrenergic receptor kinase (beta ARK) levels in the rat locus coeruleus. <i>J Neurochem</i> 63, 1983-6 (1994).	
		Barak, L.S., Warabi, K., Feng, X., Caron, M.G. & Kwatra, M.M. Real-time visualization of the cellular redistribution of G protein-coupled receptor kinase 2 and beta-arrestin 2 during homologous desensitization of the substance P receptor. <i>J Biol Chem</i> 274, 7565-9 (1999).	
		Harlan, J.E., Hajduk, P.J., Yoon, H.S. & Fesik, S.W. Pleckstrin homology domains bind to phosphatidylinositol-4,5-bisphosphate. <i>Nature</i> 371, 168-70 (1994).	
		DeBurman, S.K., Ptasienski, J., Benovic, J.L. & Hosey, M.M. G protein-coupled receptor kinase GRK2 is a phospholipid-dependent enzyme that can be conditionally activated by G protein betagamma subunits. <i>J Biol Chem</i> 271, 22552-62 (1996).	

Examiner
Signature

Date
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take .2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

+

PTO/SB/08B (6-95)

Approved for use through 07/31/96, OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

1449B/PTO
Rev. 10/95U.S. Department of Commerce
Patent and Trademark Office

Complete if Known

LIST OF PRIOR ART CITED BY
APPLICANT

(use as many sheets as necessary)

Sheet

3

of

6

Application Number

10/524,060

Filing Date

February 8, 2005

First Named Inventor

Zhiming SUO, M.D., Ph.D.

Group Art Unit

1649

Examiner Name

WANG, Chang Yu

Attorney Docket Number

US 1421/05 (VA)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book), magazine, journal, serial, symposium, catalog, etc., date, page(s), volume-issue number(s), Publisher, country, where published, source.	T ²
		Freeman, J.L., Pitcher, J.A., Li, X., Bennett, V. & Lefkowitz, R.J. alpha-Actinin is a potent regulator of G protein-coupled receptor kinase activity and substrate specificity in vitro. <i>FEBS Lett</i> 473, 280-4 (2000).	
		Roth, G.S., Joseph, J.A. & Mason, R.P. Membrane alterations as causes of impaired signal transduction in Alzheimer's disease and aging. <i>Trends Neurosci</i> 18, 203-6 (1995).	
		Price, D.L. et al. Sequestration of tubulin in neurons in Alzheimer's disease. <i>Brain Res</i> 385, 305-10 (1986).	
		Wallace, M.A. Effects of Alzheimer's disease-related beta amyloid protein fragments on enzymes metabolizing phosphoinositides in brain. <i>Biochim Biophys Acta</i> 1227, 183-7 (1994).	
		Mattson, M.P. et al. beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. <i>J Neurosci</i> 12, 376-89 (1992).	
		Chishti, M.A. et al. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of APP695. <i>J Biol Chem</i> 15, 276(24):21562-70 (2001).	
		Schutzer, W.E., Reed, J.F., Bliziotis, M. & Mader, S.L. Upregulation of G protein-linked receptor kinases with advancing age in rat aorta. <i>Am J Physiol Regul Integr Comp Physiol</i> 280, R897-903 (2001).	
		Griffin, W.S. et al. Glial-neuronal interactions in Alzheimer's disease: the potential role of a 'cytokine cycle' in disease progression. <i>Brain Pathol</i> 8, 65-72 (1998).	
		Suo, Z. et al. Participation of protease-activated receptor-1 in thrombin-induced microglial activation. <i>J Neurochem</i> 80, 655-66 (2002).	
		Crawford, F. et al. Alzheimer's beta-amyloid vasoactivity: identification of a novel beta- amyloid conformational intermediate. <i>FEBS Lett</i> 436, 445-8 (1998).	

Examiner
SignatureDate
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take .2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

+

PTO/SB/08B (6-95)

Approved for use through 07/31/96, OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

1449B/PTO
Rev. 10/95U.S. Department of Commerce
Patent and Trademark Office

Complete if Known

LIST OF PRIOR ART CITED BY
APPLICANT

(use as many sheets as necessary)

Sheet

4

of

6

Application Number

10/524,060

Filing Date

February 8, 2005

First Named Inventor

Zhiming SUO, M.D., Ph.D.

Group Art Unit

1649

Examiner Name

WANG, Chang Yu

Attorney Docket Number

US 1421/05 (VA)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book), magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), Publisher, country, where published, source.	T ²
		Tiruppathi, C. et al. G protein-coupled receptor kinase-5 regulates thrombin-activated signaling in endothelial cells. <i>Proc Natl Acad Sci U S A</i> 97, 7440-5 (2000).	
		Shapiro, M.J., Weiss, E.J., Faruqi, T.R. & Coughlin, S.R. Protease-activated receptors 1 and 4 are shut off with distinct kinetics after activation by thrombin. <i>J Biol Chem</i> 275, 25216-21. (2000).	
		Noda, M., Nakanishi, H., Nabekura, J. & Akaike, N. AMPA-kainate subtypes of glutamate receptor in rat cerebral microglia. <i>J Neurosci</i> 20, 251-8 (2000).	
		Hajjar, A.M., Ernst, R.K., Tsai, J.H., Wilson, C.B. & Miller, S.I. Human Toll-like receptor 4 recognizes host-specific LPS modifications. <i>Nat Immunol</i> 3, 354-9 (2002).	
		Stanciu, M. et al. Persistent activation of ERK contributes to glutamate-induced oxidative toxicity in a neuronal cell line and primary cortical neuron cultures. <i>J Biol Chem</i> 275, 12200-6 (2000).	
		Iversen, L.L., Mortishire-Smith, R.J., Pollack, S.J. & Shearman, M.S. The toxicity in vitro of beta-amyloid protein. <i>Biochem J</i> 311, 1-16 (1995).	
		Meda, L. et al. Activation of microglial cells by beta-amyloid protein and interferon- gamma. <i>Nature</i> 374, 647-50 (1995).	
		Lue, L.F. et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. <i>Am J Pathol</i> 155(3):853-62 (1999).	
		Sigurdsson, E.M., Scholtzova, H., Mehta, P.D., Frangione, B. & Wisniewski, T. Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. <i>Am J Pathol</i> 159, 439-47. (2001).	
		Lewis, J. et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. <i>Science</i> 293, 1487-91 (2001).	

Examiner
SignatureDate
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take .2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

+

PTO/SB/08B (6-95)
 Approved for use through 07/31/96, OMB 0651-0031
 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

1449B/PTO
 Rev. 10/95

U.S. Department of Commerce
 Patent and Trademark Office

LIST OF PRIOR ART CITED BY APPLICANT

(use as many sheets as necessary)

Sheet

5

of

6

Complete if Known

Application Number	10/524,060
Filing Date	February 8, 2005
First Named Inventor	Zhiming SUO, M.D., Ph.D.
Group Art Unit	1649
Examiner Name	WANG, Chang Yu
Attorney Docket Number	US 1421/05 (VA)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book), magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), Publisher, country, where published, source.	T ²
		Sandhu, F.A. et al. NMDA and AMPA receptors in transgenic mice expressing human beta- amyloid protein. <i>J Neurochem</i> 61, 2286-9. (1993).	
		Smith, D.H. et al. Brain trauma induces massive hippocampal neuron death linked to a surge in beta-amyloid levels in mice overexpressing mutant amyloid precursor protein. <i>Am J Pathol</i> 153, 1005-10 (1998).	
		Aragay, A.M. et al. Monocyte chemoattractant protein-1-induced CCR2B receptor desensitization mediated by the G protein-coupled receptor kinase 2. <i>Proc Natl Acad Sci U S A</i> 95, 2985-90 (1998).	
		Crawford, F., Suo, Z., Fang, C. & Mullan, M. Characteristics of the in vitro vasoactivity of beta-amyloid peptides. <i>Exp Neurol</i> 150, 159-68 (1998).	
		Suo, Z. et al. Soluble Alzheimers beta-amyloid constricts the cerebral vasculature in vivo. <i>Neurosci Lett</i> 257, 77-80 (1998).	
		Federal Interagency Forum on Aging-Related Statistics. 2000. Older Americans 2000: Key Indicators of Well-Being. Web site: http://www.agingstats.gov/chartbook2000/population.html . (January 14, 2002.)	
		FMG Innovations dba Alzheimer's Test Kit. 2001. Early Alert Alzheimer's Home Screening Test. April 23, 2001. Web site: http://www.alzheimerstestkit.com/(October 8, 2001.)	
		Fraser P. E., G. Yu, L. Levesque, M. Nishimura, D. S. Yang, H. T. J. Mount, D. Westaway, and P. H. St-George-Hyslop. February 2001. Presenilin function: connections to Alzheimer's disease and signal transduction. <i>Biochemical Society Symposia</i> 67:89-100.	
		Freeman J. L., E. M. De La Cruz, T. D. Pollard, R. J. Lefkowitz, and J. A. Pitcher. August 7, 1998. Regulation of G protein-coupled receptor kinase 5 (GRK5) by actin. <i>Journal of Biological Chemistry</i> 273(32):20653-20657.	
		Market News Publishing Inc. 2001. Nycomed Amersham Imaging and Neurochem collaborate to create Alzheimer's diagnostic. <i>Intelihealth Inc.</i> July 19, 2001. Web site: http://ipn.intelihealth.com/IPN/ihIPN/WSIPN000/23883/7194/328776.html . (October 8, 2001.)	

Examiner
 Signature

Date
 Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take .2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

+

PTO/SB/08B (6-95)

Approved for use through 07/31/96, OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

1449B/PTO
Rev. 10/95U.S. Department of Commerce
Patent and Trademark Office**Complete if Known****LIST OF PRIOR ART CITED BY
APPLICANT**

(use as many sheets as necessary)

Sheet

6

of

6

Application Number

10/524,060

Filing Date

February 8, 2005

First Named Inventor

Zhiming SUO, M.D., Ph.D.

Group Art Unit

1649

Examiner Name

WANG, Chang Yu

Attorney Docket Number

US 1421/05 (VA)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Item (book), magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), Publisher, country, where published, source.	T ²
		McLean C. A., R. A. Cherny, F. W. Fraser, S. J. Fuller, M. J. Smith, K. Beyreuther, Al Bush, and C. L. Masters. December 1999. Soluble pool of A β amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. <i>Annals of Neurology</i> 46:860-866.	
		Medical Devicelink. 1997. Test developers pursue early Alzheimer's disease diagnostic. <i>IVD Technology Magazine</i> . March 1997. Web site: http://www.devicelink.com/ivdt/archive/97/03/003.html . (October 8, 2001.)	
		National Institute on Aging. 2001. <i>Alzheimer's Disease Fact Sheet</i> . Alzheimer's Disease Education & Referral Center, National Institute on Aging, National Institutes of Health. 2001. Web site: http://www.alzheimers.org/pubs/adfact.html (December 5, 2002.)	
		National Institutes of Health. 1994. <i>Alzheimer's Disease</i> . Web site: http://www.pueblo.gsa.gov/cic_text/health/alzheim/alzheim.htm . (October 8, 2001.)	
		Neve R. L., D. L. McPhie, and Y. Chen. February 2001. Alzheimer's disease: dysfunction of a signalling pathway mediated by the amyloid precursor protein? <i>Biochemical Society Symposia</i> 67:37-50.	
		O'Neill C., R. F. Cowburn, W. L. Bonkale, T. G. Ohm, J. Fastbom, M. Carmody, and M. Kelliher. February 2001. Dysfunctional intracellular calcium homeostasis: a central cause of neurodegeneration in Alzheimer's disease. <i>Biochemical Society Symposia</i> 67:177-194.	
		Pitcher J. A., R. A. Hall, Y. Daaka, J. Zhang, S. S.G. Ferguson, S. Hester, S. Miller, M. G. Caron, R. J. Lefkowitz, and L. S. Barak. May 15, 1998. The G protein-coupled receptor kinase 2 is a microtubule-associated protein kinase that phosphorylates tubulin. <i>Journal of Biological Chemistry</i> 273(20):12316-12324.	
		Silva, Chris. 2001. Joining the great chase: Rockville biotech firm is among those racing to find an Alzheimer's cure. <i>Washington Business Journal</i> . May 25, 2001. Web site: http://washington.bcentral.com/washington/stories/2001/05/28/focus1.html . (October 8, 2001.)	
		Strittmatter W. J. February 2001. Apolipoprotein E and Alzheimer's disease: signal transduction mechanisms. <i>Biochemical Society Symposia</i> 67:101-109.	
		Suo Z., M. Wu, S. Ameenuddin, H. E. Anderson, J. E. Zoloty, B. A. Citron, P. Andrade-Gordon, and B. W. Festoff. February 2002. Participation of protease-activated receptor-1 in thrombin-induced microglial activation. <i>Journal of Neurochemistry</i> 80(4):655-666.	

Examiner
Signature

Date

Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take .2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.